A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design

By afschroeder • March 31, 2026

Wazni OM, Chun KJ, Amin A, Anic A, Ajijola OA, Gibson DN, Mansour M, Makati K, Chrispin J, Duytschaever M, Nair DG, Piccini JP, Natale A, Raciti G, Wehrenberg S, McCammon S, Albrecht EM, Garlitski A, Sutton BS, Andrade JG; AVANT GUARD Investigators. A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design. Heart Rhythm O2. 2025 Dec 23;7(3):561-574. doi: 10.1016/j.hroo.2025.12.011. PMID: 41908201; PMCID: PMC13031045.

Tags: antiarrhythmic drugs, Cardiology/Epi, catheter ablation, First-line therapy, persistent atrial fibrillation, Publications, pulsed field ablation, Randomized Controlled Trial

Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a retrospective longitudinal study

Ebrahimi R, Dennis PA, Alvarez CA, Shroyer AL, Beckham JC, Sumner JA. Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a[...]

Pulmonary Alveolar Proteinosis: Rethinking Surfactant Homeostasis Through Alveolar Macrophage Lipid-Handling Dysfunction

Lee E, Little IJ, Dantas L, Tarling EJ. Pulmonary Alveolar Proteinosis: Rethinking Surfactant Homeostasis Through Alveolar Macrophage Lipid-Handling Dysfunction. Arterioscler Thromb Vasc Biol. 2026 Sep[...]

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors

Zhu Y, Yu J, Kim YJ, Tian Y, Li Z, Chen Y, Lyu Z, Zhu E, Zhao AS, Ma N, Zhang C, Kramer A, Wilson[...]